TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05493501
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV Infusion over 4 fixed cycles per prescribing information.
Study: NCT04895917
Drug: daratumumab and pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
Study: NCT06757517
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).
Study: NCT06757517
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline intranasal placebo comparator
Study: NCT06773936
Drug: Post-Remission
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab, Dasatinib, Methotrexate and Dexamethasone
Study: NCT06773936
Drug: Maintenance
Normalized name: Xcopri Maintenance Pack
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asciminib, Dasatinib, Prednisone, and Methotrexate
Study: NCT06752759
Drug: nebulized ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
Study: NCT06158100
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.
Study: NCT06158100
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine will be administered at a dose of 20mg/m\^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.
Study: NCT06758700
Drug: Teniposide administration
Normalized name: Teniposide
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 5 consecutive days, with 21 days as one cycle of treatment.
Study: NCT06487572
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) Infusion
Study: NCT06487572
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) Injection
Study: NCT06611436
Drug: BE-101
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion of BE-101 dose from Dose Level 1
Study: NCT06611436
Drug: BE-101
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion of BE-101 dose from Dose Level 2
Study: NCT06611436
Drug: BE-101
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion of BE-101 dose from Dose Level 3
Study: NCT06611436
Drug: BE-101
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
Study: NCT06771219
Drug: SLV-154
Normalized name: SLV-334
DrugBank: SLV-334 (DB15356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV-154
Study: NCT06744868
Drug: THDBH120 injection (SAD)
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received escalating single doses of THDBH120 by subcutaneous injection.
Study: NCT06740552
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab 140mg every two weeks
Study: NCT06751199
Drug: human umbilical cord mesenchymal stem cells
Normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal vein infusion human umbilical cord mesenchymal stem cells
Study: NCT06751199
Drug: allogeneic islet
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal vein infusion of allogeneic islet
Study: NCT06762327
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity
Study: NCT06762431
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Level 1
Study: NCT06762431
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Level 2
Study: NCT05699408
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study: NCT06118034
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
Study: NCT05386121
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
Study: NCT05996185
Drug: Mogamulizumab
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
Study: NCT05999812
Drug: all trans Retinoic Acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
Study: NCT05999812
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab IV D1, 840 mg every 14 days
Study: NCT05999812
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab IV D1, 10 mg/kg every 14 days
Study: NCT04056910
Drug: ivosidenib and nivolumab
Normalized name: ivosidenib
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events. Nivolumab will be administered at 480 mg IV every 28 days.
Study: NCT06577558
Drug: SR1375 capsule 3mg+regular treatments
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SR1375 capsule 3mg QD orally+CAP regular treatments
Study: NCT06577558
Drug: SR1375 capsule 1mg+regular treatments
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SR1375 capsule 1mg QD orally+CAP regular treatments
Study: NCT05750290
Drug: CKD-702 in combination with irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CKD-702 and irinotecan will be intravenously administered every 2 weeks.
Study: NCT05071118
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery
Study: NCT06023329
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive SCPB with ropivacaine via regional anesthesia team
Study: NCT06023329
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive SCPB with saline via regional anesthesia team
Study: NCT06176196
Drug: VX-548
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT04943198
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/kg/day
Study: NCT06089551
Drug: SmofKabiven
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
Study: NCT06237205
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a highly selective PARP1 and PARP2 inhibitor
Study: NCT04712279
Drug: Ivermectin 0.6mg/kg/day
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of ivermectin 0.6m/kg/day q.d.for 05 days
Study: NCT04712279
Drug: Ivermectin 1.0mg/kg/day
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 1.0mg/kg/day q.d. for 05 days
Study: NCT04712279
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 200mg/day q.d. for 05 days
Study: NCT06669572
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks.
Study: NCT06669572
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be taken once daily, with or without food, at the same time each day.
Study: NCT04915183
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
Study: NCT00627835
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
Study: NCT06766565
Drug: QYJD Compound Preparation
Normalized name: compound benzoin tincture (USP) / Podophyllum preparation
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.
Study: NCT06787183
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2, d1, q3w, 2 cycles
Study: NCT06787183
Drug: QL1706
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg, q3w
Study: NCT00627835
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
Study: NCT00627835
Drug: sorafenib and cisplatin
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
Study: NCT00627835
Drug: sorafenib and cisplatin
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
Study: NCT00627835
Drug: sorafenib and cisplatin
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
Study: NCT06355401
Drug: Tamoxifen 20mg
Normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
Study: NCT06054321
Drug: stepwise pharmacotherapy
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
Study: NCT06601257
Drug: Vancomycin (IV)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin weight-based or kidney function-based dosing
Study: NCT06672822
Drug: Sodium Thiosulfate (STS)
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg/ml) will be used for injection under ultrasound guidance.
Study: NCT06769295
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
Study: NCT06767748
Drug: GZR4
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GZR4 s.c., once-weekly，treat-to-target dose
Study: NCT06767748
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: insulin degludec s.c.,once-daily，treat-to-target dose
Study: NCT06768268
Drug: Mannitol (20%)
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding Mannitol into Voluven and used as solvent of ICG
Study: NCT06766916
Drug: Crisugabalin
Normalized name: Crisugabalin
DrugBank: Crisugabalin (DB19300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-14: Crisugabalin 40 mg/day, 20 mg twice daily, orally. Days 15-21: Increase dose to 80 mg/day, 40 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 120 mg/day, 60 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.
Study: NCT06766916
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Days 1-7: Pregabalin 150 mg/day, 75 mg twice daily, orally. Days 8-14: Increase dose to 300 mg/day, 150 mg twice daily. Days 15-21: Increase dose to 450 mg/day, 225 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 600 mg/day, 300 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.
Study: NCT06767358
Drug: ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous adjunctive ketamine infusion at a fixed dose of 0.50mg/kg/hour
Study: NCT06702124
Drug: Rotigotine 4Mg/24Hrs Patch
Normalized name: ROTIGOTINE 4MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotigotine 4 mg/24Hrs administration for 24 weeks
Study: NCT05899816
Drug: Rocatinlimab
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT05641558
Drug: 611 150mg
Normalized name: 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
Study: NCT05641558
Drug: 611 300mg
Normalized name: 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
Study: NCT05641558
Drug: 611 600mg
Normalized name: 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
Study: NCT06379217
Drug: GnRH antagonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abarelix, degarelix, or relugolix
Study: NCT06379217
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATC code A03FA01
Study: NCT06560138
Drug: SHR-4602
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-4602 will be administered through IV infusion.
Study: NCT06706284
Drug: Semaglutide Injectable Product
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A GLP-1 inhibitor used to control T2DM
Study: NCT06764875
Drug: Rilvegostomig
Normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W, intravenous infusion
Study: NCT06764875
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Q3W, intravenous infusion
Study: NCT06208540
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.
Study: NCT06764875
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Q3W, intravenous infusion
Study: NCT06764875
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Q3W, intravenous infusion
Study: NCT06764875
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Q3W, intravenous infusion
Study: NCT06764875
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Q3W, intravenous infusion
Study: NCT06764875
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Q3W, intravenous infusion
Study: NCT06766500
Drug: Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablet
Study: NCT04599478
Drug: Naltrexone and Bupropion medication
Normalized name: bupropion and naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NB medication will be taken daily in pill form.
Study: NCT06734637
Drug: Peginterferon α-2b injection
Normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
Study: NCT06789679
Drug: Gemcitabine, albumin-bound paclitaxel, S-1
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w
Study: NCT06789679
Drug: Gemcitabine, albumin-bound paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w
Study: NCT05657457
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-arterial tenecteplase
Study: NCT06787976
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir + Tenofovir Disoproxil Fumarate / Emtricitabine
Study: NCT06787976
Drug: Darunavir/Cobicistat (FDC)
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir Cobicistat + TDF/FTC
Study: NCT06659718
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: New use of oral semaglutide dispensing claim is used as the exposure.
Study: NCT06659718
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: New initiation of sitagliptin dispensing claim is used as the reference.
Study: NCT05566795
Drug: Tovorafenib
Normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral type II RAF kinase inhibitor